Chris Viehbacher

Latest Headlines

Latest Headlines

Sanofi CEO vows to 'go beyond' handouts, hit double-digit growth in Africa

Just days after GlaxoSmithKline announced it would open a new R&D lab and invest more than $200 million in Africa, Sanofi CEO Chris Viehbacher is affirming his country's devotion to Africa, too.

Sanofi looks to Regeneron to salvage its R&D rep

Sanofi hasn't had much to brag about when it comes to new product launches in the 5 years since Chris Viehbacher took the helm of the pharma giant. While he's tried, not always successfully, to reinvigorate R&D--buying Genzyme in the process--new therapies have added less than a billion euros a year to the top line, according to PMLive.

Sanofi CEO: Our pipeline is in the top 5

Despite the recent FDA rebuke of the blockbuster hopeful Lemtrada, Sanofi CEO Chris Viehbacher believes his company is poised to cash in on "a whole raft of new products" in the coming years.

2014 deal outlook: Sanofi eyes $2.7B in buys; AZ analysts figure on bigger M&A

Which drugmakers are likely to be the biggest dealmakers of 2014? The direct evidence is trickling in. Sanofi CEO Chris Viehbacher, for instance, says he's looking to spend up to €2 billion on deals next year, or about $2.7 billion.

Sanofi chief's latest growth promise: Q4 will bring it

Sanofi CEO Chris Viehbacher has been talking about a return to growth for some time now. It's sort of the boy who cried wolf, but in reverse. Viehbacher hasn't been warning of a threat, he's been promising a boon.

Sanofi chief: Emerging markets are worth the hassle

On the path into emerging markets, drugmakers have stumbled across a thorny regulatory bush here, a pricing sinkhole there--not to mention a couple of big bad wolves in the form of Chinese investigators and Indian patent police. But Sanofi CEO Christopher Viehbacher figures that, whatever the obstacles, the journey will pay off.

Sanofi CEO: Thanks to Genzyme, investors take us seriously

No buyer's remorse for Sanofi CEO Chris Viehbacher. Acquiring Genzyme for $20.1 billion in 2011 has paid off handsomely, Viehbacher told the Boston Globe in an interview--and not only in terms of drug sales and new regulatory approvals.

Viehbacher: Sanofi's options include buying back stake from L'Oreal, upping stake in Regeneron

To call Sanofi's earnings release from last month "dismal" might be an understatement, but CEO Chris Viehbacher says the company has the resources to help turn earnings around. The CEO of the French drumaker says the company could make some "opportunistic" moves, and repurchasing a 9% Sanofi stake from L'Oreal or increasing its stake in Regeneron Pharmaceuticals to as much as 30% are among them.

'Brazil generics issue' costs Sanofi nearly as much as patent losses

Because Sanofi has been investing heavily in emerging markets in recent years to help it offset revenue declines from patent expirations, a 2.3%  crash in sales in those markets was a big surprise.

Sanofi CEO can't sugar-coat 'shocking' Q2 results

Call it what you will: chutzpah, optimism, wishful thinking, spin-doctoring, or just plain confidence. In any case, the headline on Sanofi's earnings release--"Last Quarter with Significant Negative Impact from Patent Cliff"--was one of the few positive statements on the page.